- Home
- FORR vs CHRS Comparison
FORR vs CHRS Comparison
Compare FORR & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- CHRS
- Stock Information
- Founded
- FORR 1983
- CHRS 2010
- Country
- FORR United States
- CHRS United States
- Employees
- FORR N/A
- CHRS N/A
- Industry
- FORR Diversified Commercial Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FORR Consumer Discretionary
- CHRS Health Care
- Exchange
- FORR Nasdaq
- CHRS Nasdaq
- Market Cap
- FORR 169.1M
- CHRS 186.0M
- IPO Year
- FORR 1996
- CHRS 2014
- Fundamental
- Price
- FORR $7.42
- CHRS $1.13
- Analyst Decision
- FORR
- CHRS Strong Buy
- Analyst Count
- FORR 0
- CHRS 4
- Target Price
- FORR N/A
- CHRS $4.51
- AVG Volume (30 Days)
- FORR 132.1K
- CHRS 1.3M
- Earning Date
- FORR 10-30-2025
- CHRS 11-06-2025
- Dividend Yield
- FORR N/A
- CHRS N/A
- EPS Growth
- FORR N/A
- CHRS N/A
- EPS
- FORR N/A
- CHRS 1.34
- Revenue
- FORR $403,871,000.00
- CHRS $277,728,000.00
- Revenue This Year
- FORR N/A
- CHRS N/A
- Revenue Next Year
- FORR $1.04
- CHRS $109.48
- P/E Ratio
- FORR N/A
- CHRS $0.84
- Revenue Growth
- FORR N/A
- CHRS 152.07
- 52 Week Low
- FORR $7.07
- CHRS $0.71
- 52 Week High
- FORR $17.65
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- FORR 35.15
- CHRS 29.26
- Support Level
- FORR $7.38
- CHRS $1.09
- Resistance Level
- FORR $8.08
- CHRS $1.39
- Average True Range (ATR)
- FORR 0.46
- CHRS 0.13
- MACD
- FORR 0.01
- CHRS -0.05
- Stochastic Oscillator
- FORR 12.36
- CHRS 5.59
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.